Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-21-026457
Filing Date
2021-11-12
Accepted
2021-11-12 16:00:53
Documents
69
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20210930_10q.htm   iXBRL 10-Q 1864081
2 EXHIBIT 31.1 ex_303768.htm EX-31.1 8488
3 EXHIBIT 31.2 ex_303769.htm EX-31.2 8482
4 EXHIBIT 32.1 ex_303771.htm EX-32.1 4245
5 EXHIBIT 32.2 ex_303772.htm EX-32.2 4244
  Complete submission text file 0001437749-21-026457.txt   8013271

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA navb-20210930.xsd EX-101.SCH 56168
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20210930_cal.xml EX-101.CAL 42020
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20210930_def.xml EX-101.DEF 457926
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20210930_lab.xml EX-101.LAB 364129
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20210930_pre.xml EX-101.PRE 485731
11 EXTRACTED XBRL INSTANCE DOCUMENT navb20210930_10q_htm.xml XML 1302027
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 211403186
SIC: 2835 In Vitro & In Vivo Diagnostic Substances